Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowy

Showing results (371-380 of 401) with videos related to

Pageof 41
Sort By:
Nature Cancer|November 11, 2024
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein exportBrajendra K Tripathi, Nicole H Hirsh, Xiaolan Qian, et al.
The Lancet. Oncology|August 26, 2011
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine TrialAimée R Kreimer, Paula González, Hormuzd A Katki, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assayHilary A Robbins, Tim Waterboer, Carolina Porras, et al.
The Journal of Infectious Diseases|August 2, 2012
Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa RicaFelipe A Castro, Wim Quint, Paula Gonzalez, et al.
The Lancet. Infectious Diseases|July 19, 2025
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trialBernal Cortés, Rebeca Ocampo, Carolina Porras, et al.
Vaccine|January 26, 2018
Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studiesAimée R Kreimer, Rolando Herrero, Joshua N Sampson, et al.
NPJ Vaccines|March 30, 2022
HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trialSabrina H Tsang, John T Schiller, Carolina Porras, et al.
Human Vaccines & Immunotherapeutics|April 11, 2013
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine TrialMahboobeh Safaeian, Troy J Kemp, David Yuanji Pan, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2020
Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infectionRaymond A Harvey, Jeremy A Rassen, Carly A Kabelac, et al.
JAMA Internal Medicine|February 24, 2021
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future InfectionRaymond A Harvey, Jeremy A Rassen, Carly A Kabelac, et al.
Pageof 41

Showing results (371-380 of 401) with videos related to

Sort By:
Pageof 41
Nature Cancer|November 11, 2024
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein exportBrajendra K Tripathi, Nicole H Hirsh, Xiaolan Qian, et al.
The Lancet. Oncology|August 26, 2011
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine TrialAimée R Kreimer, Paula González, Hormuzd A Katki, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assayHilary A Robbins, Tim Waterboer, Carolina Porras, et al.
The Journal of Infectious Diseases|August 2, 2012
Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa RicaFelipe A Castro, Wim Quint, Paula Gonzalez, et al.
The Lancet. Infectious Diseases|July 19, 2025
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trialBernal Cortés, Rebeca Ocampo, Carolina Porras, et al.
Vaccine|January 26, 2018
Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studiesAimée R Kreimer, Rolando Herrero, Joshua N Sampson, et al.
NPJ Vaccines|March 30, 2022
HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trialSabrina H Tsang, John T Schiller, Carolina Porras, et al.
Human Vaccines & Immunotherapeutics|April 11, 2013
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine TrialMahboobeh Safaeian, Troy J Kemp, David Yuanji Pan, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2020
Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infectionRaymond A Harvey, Jeremy A Rassen, Carly A Kabelac, et al.
JAMA Internal Medicine|February 24, 2021
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future InfectionRaymond A Harvey, Jeremy A Rassen, Carly A Kabelac, et al.
Pageof 41